Check out today's top analyst calls from around Wall Street, compiled by The Fly.

ANALYSTS CUT APPLE AFTER LOWERED FORECAST: Loop Capital analyst Ananda Baruah downgraded Apple (AAPL) to Hold from Buy and lowered his price target to $160 from $225 after its Q1 guidance cut Wednesday. The analyst said the announcement "greatly reduces the visibility" of the company's revenue trajectory in the medium term and puts its valuation into question. Baruah also warned that sales may be declining through the first half of 2019, since Apple is not looking forward to a material iPhone cycle in the upcoming iteration of the product and believes that investors may be leery of paying a premium for the stock without better visibility on iPhone demand improvement.

Jefferies analyst Timothy O'Shea downgraded Apple to Hold from Buy and cut his price target for the shares to $160 from $225. Apple's business in China appears to be "rapidly deteriorating" with the revised outlook for iPhone "materially worse" than expected, O'Shea told investors in a research note. The analyst still thinks Apple can build a "massive" Services business over time, but he noted that the company "hasn't missed its guide in years." As such, the extent of the fiscal Q1 miss suggests Apple is "navigating uncharted waters," said O'Shea. He moves to the sidelines pending clarity as "uncertainty grows around the hardware business." The analyst now models 185M iPhone sales in fiscal 2019, down 10% from his prior estimate of 206M.

ALPHABET UPGRADED TO BUY AT CANACCORD: Canaccord analyst Michael Graham upgraded Alphabet (GOOG, GOOGL) to Buy from Hold. The analyst said revenue growth should continue in the 15-20% range for 2-3 years which coupled with abating margin pressure and share buybacks, should lead to over 15% earnings growth between 2020-2022. He also believes competitive risks from Amazon (AMZN) are manageable and considers the stock to be the most defensive of the FANG group given its steady performance and reasonable valuation. Graham raised his price target to $1,250 from $1,140 on Alphabet shares.

FIRST SOLAR UPGRADED TO BUY AT GOLDMAN: Goldman Sachs analyst Brian Lee upgraded First Solar (FSLR) to Buy from Neutral and raised his price target for the shares to $57 from $48. Solar stocks underperformed in 2018 as tariffs, China policy and oversupply drove a cyclical correction, Lee told investors in a research note on the sector. However, heading into 2019, the analyst believes "green shoots are emerging." He said demand is improving, selling prices are stabilizing, and China is likely a positive catalyst in terms of policy. As such, Lee raised his Solar coverage view to Neutral and upgraded First Solar and Canadian Solar (CSIQ) to Buy. He thinks First Solar shares offer an attractive risk/reward at current levels. The analyst names the company the "best U.S. utility-scale play and value in solar."

LUMBER LIQUIDATORS CUT TO HOLD AT LOOP: Loop Capital analyst Laura Champine downgraded Lumber Liquidators (LL) to Hold from Buy and cut her price target for the shares to $10 from $24. The analyst reduced her margin forecast to reflect a promotional environment. In 2019, lower sales and margins are likely as big-ticket home-related spending growth begins to fade, Champine said in a research note. The analyst's 35c earnings per share estimate for Lumber Liquidators's 2019 is 20c lower than the consensus. However, she believes the stock's "trough valuation" should limit further downside.

ABBVIE CUT TO NEUTRAL AT BOFA: BofA/Merrill analyst Jason Gerberry downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality." The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.